Pargyline

Summary

Pargyline (CHEMBL673) is an approved small molecule (ATC C02KC01) targeting MAOB; indicated across 1 condition including hypertensive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C02KC01
• Targets: 1 (MAOB)
• Indications: 1 condition
• Chemistry: 159.23 Da · C11H13N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL673
Name	Pargyline
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4688
ATC	C02KC01
Molecular formula	C11H13N
Molecular weight	159.23
InChIKey	DPWPWRLQFGFJFI-UHFFFAOYSA-N

SMILES: CN(CC#C)CC1=CC=CC=C1

IUPAC name: N-benzyl-N-methylprop-2-yn-1-amine

Also known as: Eutron, Pargilina, Pargyline, pargyline, SID11111668, SID11111669, SID90340843, PARGYLINE

Parent form; salt/anhydrous children: CHEMBL1200425

Patent coverage: 3,378 distinct patent families (11,884 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
MAOB	Monoamine oxidase B	Inhibition	5.74	0%	P27338

Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Ubiquitin carboxyl-terminal hydrolase 2, Prelamin-A/C, Amine oxidase [flavin-containing] A, Thyrotropin receptor, Amine oxidase [flavin-containing] B, Aldehyde dehydrogenase, mitochondrial, Amine oxidase [flavin-containing] B, Amine oxidase [flavin-containing] A, Cytochrome P450 3A4, Pyrroline-5-carboxylate reductase 1, mitochondrial.

Bioactivity

ChEMBL activities: 68 potent at pChembl ≥ 5 of 76 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MAOB	8.09	IC50	8.2	nM	CHEMBL_ACT_18515024
MAOA	7.94	IC50	11.52	nM	CHEMBL_ACT_18515023
MAOB	7.69	Ki	20.3	nM	CHEMBL_ACT_15163801
MAOB	7.32	IC50	48	nM	CHEMBL_ACT_24761471
MAOB	7.3	Ki	49.5	nM	CHEMBL_ACT_15163794
MAOB	7.14	IC50	72	nM	CHEMBL_ACT_29250609
MAOB	7.12	IC50	75.2	nM	CHEMBL_ACT_18744368
MAOB	7.1	IC50	80	nM	CHEMBL_ACT_23198050
MAOB	7.1	IC50	79	nM	CHEMBL_ACT_26046763
MAOB	7.07	IC50	85.8	nM	CHEMBL_ACT_19098411
MAOB	7.04	IC50	91	nM	CHEMBL_ACT_19104165
MAOB	7.02	IC50	95	nM	CHEMBL_ACT_27086882
MAOB	7	IC50	100	nM	CHEMBL_ACT_19367819
MAOB	6.99	IC50	103	nM	CHEMBL_ACT_19448184
MAOB	6.97	IC50	107.3	nM	CHEMBL_ACT_20685932
MAOB	6.92	IC50	120	nM	CHEMBL_ACT_18494013
MAOB	6.92	IC50	120	nM	CHEMBL_ACT_22750595
TSHR	6.9	Potency	125.9	nM	CHEMBL_ACT_3918797
MAOB	6.89	IC50	130	nM	CHEMBL_ACT_13453969
MAOB	6.89	IC50	130	nM	CHEMBL_ACT_15625529
MAOB	6.86	IC50	137	nM	CHEMBL_ACT_29247288
MAOB	6.85	IC50	140	nM	CHEMBL_ACT_29220962
MAOB	6.82	IC50	150	nM	CHEMBL_ACT_19045119
MAOB	6.82	IC50	150	nM	CHEMBL_ACT_29154511
MAOB	6.73	IC50	188	nM	CHEMBL_ACT_12667418
MAOB	6.73	IC50	188	nM	CHEMBL_ACT_13844631
MAOB	6.73	IC50	188	nM	CHEMBL_ACT_15632275
MAOB	6.73	IC50	188	nM	CHEMBL_ACT_18365600
MAOB	6.72	IC50	192	nM	CHEMBL_ACT_15144163
MAOB	6.71	IC50	195	nM	CHEMBL_ACT_16817712

Target pathways

Aggregated over 1 target gene(s): MAOB.

Top Reactome pathways

5 total, by targets touching each:

Pathway	Targets	Genes
Amine Oxidase reactions	1	MAOB
Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB	1	MAOB
Metabolism	1	MAOB
Biological oxidations	1	MAOB
Phase I - Functionalization of compounds	1	MAOB

Dominant GO biological processes

GO term	Targets
substantia nigra development	1
dopamine catabolic process	1
hydrogen peroxide biosynthetic process	1

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypertensive disorder	4	MONDO:0005044	EFO:0000537

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

48 molecules share ≥1 primary target. Top 48 by shared-target count:

Molecule	Source	Status	Shared targets
TEDIZOLID	ChEMBL + PubChem	Phase 4 (approved)	MAOB
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	MAOB
DANTHRON	ChEMBL	Phase 4 (approved)	MAOB
DONEPEZIL	ChEMBL	Phase 4 (approved)	MAOB
FENTANYL	ChEMBL	Phase 4 (approved)	MAOB
IPRONIAZID	ChEMBL	Phase 4 (approved)	MAOB
ISTRADEFYLLINE	ChEMBL	Phase 4 (approved)	MAOB
LINEZOLID	ChEMBL	Phase 4 (approved)	MAOB
MENADIONE	ChEMBL	Phase 4 (approved)	MAOB
METHYLENE BLUE CATION	ChEMBL	Phase 4 (approved)	MAOB
MICONAZOLE	ChEMBL	Phase 4 (approved)	MAOB
MOCLOBEMIDE	ChEMBL	Phase 4 (approved)	MAOB
PHENELZINE	ChEMBL	Phase 4 (approved)	MAOB
PIOGLITAZONE	ChEMBL	Phase 4 (approved)	MAOB
PRIMAQUINE	ChEMBL	Phase 4 (approved)	MAOB
RASAGILINE	ChEMBL	Phase 4 (approved)	MAOB
ROSIGLITAZONE	ChEMBL	Phase 4 (approved)	MAOB
SAFINAMIDE	ChEMBL	Phase 4 (approved)	MAOB
SELEGILINE	ChEMBL	Phase 4 (approved)	MAOB
TOLOXATONE	ChEMBL	Phase 4 (approved)	MAOB
TRANYLCYPROMINE	ChEMBL	Phase 4 (approved)	MAOB
TROGLITAZONE	ChEMBL	Phase 4 (approved)	MAOB
ZONISAMIDE	ChEMBL	Phase 4 (approved)	MAOB
CURCUMIN	ChEMBL	Phase 3	MAOB
IDAZOXAN	ChEMBL	Phase 3	MAOB
QUERCETIN	ChEMBL	Phase 3	MAOB
RESVERATROL	ChEMBL	Phase 3	MAOB
ATIBEPRONE	ChEMBL	Phase 2	MAOB
BROFAROMINE	ChEMBL	Phase 2	MAOB
CIGLITAZONE	ChEMBL	Phase 2	MAOB
CLORGILINE	ChEMBL	Phase 2	MAOB
DAIDZEIN	ChEMBL	Phase 2	MAOB
FORMONONETIN	ChEMBL	Phase 2	MAOB
GENISTEIN	ChEMBL	Phase 2	MAOB
HYMECROMONE	ChEMBL	Phase 2	MAOB
LADOSTIGIL	ChEMBL	Phase 2	MAOB
LAZABEMIDE	ChEMBL	Phase 2	MAOB
LOFLUCARBAN	ChEMBL	Phase 2	MAOB
LUTEOLIN	ChEMBL	Phase 2	MAOB
MOFEGILINE	ChEMBL	Phase 2	MAOB
MOLIBRESIB	ChEMBL	Phase 2	MAOB
PHENAMAZOLINE	ChEMBL	Phase 2	MAOB
PIPERINE	ChEMBL	Phase 2	MAOB
SEMBRAGILINE	ChEMBL	Phase 2	MAOB
SUTEZOLID	ChEMBL	Phase 2	MAOB
TIOXOLONE	ChEMBL	Phase 2	MAOB
VAFIDEMSTAT	ChEMBL	Phase 2	MAOB
Medroxyprogesterone	PubChem	Approved	MAOB